Phase 1/2 Multicenter Study of KYV-101 Anti-CD19 CAR T-Cell Therapy in Refractory Lupus Nephritis

The primary objective of this study is to evaluate the safety and efficacy of **KYV-101**, an autologous fully-human anti-CD19 chimeric antigen receptor T-cell (CD19 CAR T) therapy, in subjects with refractory **Lupus Nephritis**. This investigation is clinically relevant as it aims to address the unmet medical need in patients who do not respond to conventional treatments, potentially offering a novel therapeutic option for this challenging condition.

The clinical trial focuses on **Lupus Nephritis** and includes both male and female participants. The study population encompasses individuals from two age categories, specifically adults and adolescents. The trial involves a vulnerable population, indicating that special considerations are in place to ensure participant safety and ethical conduct. However, the sponsor has not provided information regarding the total number of participants involved in the study. The selection of the trial population is not detailed, and no specific lifestyle considerations such as diet, physical activity, or habits are mentioned. Key inclusion or exclusion criteria are not specified in the available data.

The clinical trial is designed to evaluate the safety and efficacy of **KYV-101**, an autologous fully-human anti-CD19 chimeric antigen receptor T-cell (CD19 CAR T) therapy, in subjects with refractory **lupus nephritis**. This study is structured as a Phase 1/2, open-label, multicenter trial. The trial is expected to commence recruitment on July 25, 2023, and is projected to conclude by July 25, 2040. Participants will be involved in the study for a duration that aligns with the trial's objectives and endpoints, although specific timelines for individual participation are not detailed in the available data.

The trial will include a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will undergo a series of follow-up visits to monitor the therapy's effects and any adverse events. The end-of-study visit will conclude the participant's involvement, where final assessments will be conducted to evaluate the overall outcomes of the treatment. Conditions that may lead to early termination from the study include the occurrence of significant adverse events or the participant's decision to withdraw consent.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is set to commence recruitment on July 25, 2023, with an estimated completion date of July 25, 2040. The trial is categorized under phase 7, indicating an advanced stage of clinical research. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely employ standard methodologies for measuring and analyzing efficacy outcomes. These may include validated scales, laboratory tests, or patient-reported outcomes, assessed at predetermined timepoints throughout the trial duration. The absence of explicit endpoints suggests a focus on comprehensive data collection to evaluate the therapeutic impact of the intervention under investigation. The trial's design will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy assessments.